Emergent Biosolutions Inc. income statement

In fiscal 2025, Emergent Biosolutions Inc. reported revenue of $743m, down 28.8% on the year before, operating income of $100m (a 13.5% margin) and net income of $52.6m, or $0.93 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Emergent Biosolutions Inc.: income statement, annual
Fiscal year	2009Dec 2009	2010Dec 2010	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMSept 2026
Revenue	235	286	273	282	313	450	523	489	561	782	1,106	1,577	1,774	1,118	1,049	1,044	743	649
Cost of revenue	—	—	—	—	—	—	—	126	188	322	434	537	748	693	705	681	326	335
Gross profit	—	—	—	—	—	—	—	363	373	460	673	925	891	383	318	362	417	314
Research and development	75	89	125	120	120	105	119	107	97	143	226	238	235	188	111	71	53	41
Selling, general and administrative	74	76	74	76	88	109	121	143	143	203	274	304	349	340	368	308	186	189
Operating income	40	74	32	30	43	89	142	106	124	90	114	439	341	−170	−726	−109	100	−180
Interest expense	0	0	0	0	0	8	7	8	7	10	38	31	35	37	88	71	59	45
Income before tax	42	73	32	32	43	84	136	99	119	82	77	412	303	−219	−731	−143	83	−240
Income tax	15	26	16	14	13	30	44	37	36	19	23	106	84	−7	29	48	30	21
Net income	31	52	23	24	31	37	63	52	83	63	55	306	220	−212	−761	−191	53	−261
Diluted EPS	$0.99	$1.59	$0.64	$0.65	$0.85	$0.88	$1.41	$1.13	$1.71	$1.22	$1.04	$5.68	$4.06	−$4.22	−$14.85	−$3.60	$0.93	−$4.78
Diluted shares (average)	31m	33m	36m	36m	37m	46m	47m	49m	50m	51m	52m	54m	54m	50m	51m	53m	57m	55m
EBITDA	45	80	41	41	60	112	165	134	157	126	164	489	465	−27	−601	0	196	−120

US$ millions unless shown otherwise. Fiscal quarters.

Emergent Biosolutions Inc.: income statement, quarterly
Quarter	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026	2026 Q3Sept 2026
Revenue	195	222	141	231	149	156	234	110
Cost of revenue	118	89	67	86	85	72	97	81
Gross profit	77	134	74	145	64	84	137	29
Research and development	9	15	13	14	12	11	9	9
Selling, general and administrative	61	52	44	39	51	47	45	47
Operating income	−10	50	2	77	−28	11	−125	−37
Interest expense	15	15	15	15	15	11	10	10
Income before tax	−28	93	−17	58	−51	13	−166	−36
Income tax	4	25	−5	6	4	7	14	−4
Net income	−31	68	−12	51	−55	7	−180	−33
Diluted EPS	−$0.57	$1.19	−$0.22	$0.91	−$0.96	$0.07	−$3.49	−$0.64
EBITDA	17	75	9	84	−4	34	−118	−31

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: EBS vs TVTX ALVO vs EBS AMPH vs EBS

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Emergent Biosolutions Inc.'s SEC filings (10-K and 10-Q), retrieved November 3, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Emergent Biosolutions Inc.